Radleys has announced sales of its parallel chemistry and laboratory reactor products have contributed to a 400% growth in its Asian business during 2004-5 and 2005-6
Reflecting on the spectacular business growth, Mark Radley, managing director, commented: "In recent years a growing proportion of our traditional pharmaceutical and biotech industry customers in Europe and North America have started to relocate part of their R+D to Asia.
"Consequently we have increased our resource allocation to the region and have seen companies including Sabic, Nicholas Piramal, Altana, GVK, Syngene, Dr Reddys, Advinus and Torrent investing in technology such as the Carousel, GreenHouse and Lara product ranges, to enable them to either win contracts from US or European pharma/biotech companies or to develop their own R+D programs'.
Radleys says it is the market leader for low cost parallel chemistry tools, offering an unrivalled range of affordable synthesisers, evaporation and work-up systems to aid productivity of chemists from industry to academia.
Born out of 40 years experience of developing affordable glass reactor system - process development laboratories have welcomed the ease of use, versatility, affordability and improvements in process efficiency offered by the innovative Lara CLR (controlled laboratory reactor) range.
